Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axicabtagene ciloleucel in relapsed or refractory primary mediastinal B-cell lymphoma
2024-510972-19-00Phase 2Completed
- Sponsor
- Universität Münster
- Start
- Feb 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axicabtagene ciloleucel in primary mediastinal large B-cell lymphoma (PMBCL), sponsored by Universität Münster. Primary endpoint: Complete metabolic remission rate at 3 months. Started Feb 2025; status: completed.
02
Drugs
axicabtagene ciloleucel
03
Conditions
primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on 2024-510972-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510972-19-00.